Management of Fungal Infection in Neutropenic Patients with Fluconazole

Publisher Website
Google Scholar
Abstract
Fluconazole is a new orally absorbed antifungal azole which is soluble in water. It has a half-life of 24–30 h in humans [1], and is being evaluated in the treatment of localized and systemic fungal infections using a simple once daily oral or intravenous dosing regimen. Early clinical results with fluconazole have demonstrated it to be effective in the treatment of candidosis of the oropharynx, oesophagus, urinary tract and a variety of deep tissue sites at a daily dosage of 50–100 mg/day [2–6]. There are also reports of efficacy in the treatment of cryptococcal meningitis [7–9]. The ready penetration of fluconazole into the CSF is highly relevant in this context [10].

This publication has 8 references indexed in Scilit: